ProCE Banner Activity

Phase III Trial: Bone and Renal Effects With Denosumab vs Zoledronic Acid in Newly Diagnosed MM

Slideset Download
Conference Coverage
Results of this large international phase III trial showed that denosumab was associated with significantly less renal toxicity and prolonged PFS vs zoledronic acid in patients with newly diagnosed MM.

Released: June 14, 2017

Expiration: June 13, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology